Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets
D0817C00098
Phase 3 small_molecule active
Quick answer
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets for BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active